Research papers

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR) URL

The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513798/

Conclusion: According to the provided literature overview, we firmly believe that GcMAF deserves be tested as immune-therapeutic to increase macrophages functionality for earlier SARS-CoV-2 viral control, protection against COVID-19 progression by limiting epithelial damage, control local inflammation and prevent from the hyperinflammatory immune response. For this purpose, we planned a Phase-II interventional clinical trial evaluating the effectiveness and safety of Oral immunotherapy with Third Generation GcMAF in hospitalized patients with COVID-19 pneumonia (COral-MAF1 Trial) at the “Ospedale del Mare” Hospital, Naples, Italy.

ru20200402
«Иммунотерапия», как новая надежда в лечении нарушений развития у детей
DevelopmentofcolostrumMAF
Development of colostrum MAF and its clinical application
CaseReportGcMAFTreatment
Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis
MacrophagesExhibit
Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors
CaseReportANon-small
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields
Degalactosylated
Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity
ClinicalExperience
Clinical Experience of Integrative Cancer Immunotherapy with GcMAF
EstablishmentofaMacro
Establishment of a Macrophage-activating Factor Assay System Using the Human Monocytic Cell Line THP-1
OralColostrumMacrophage
Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports
CaseReportABreastCancer
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy
ANTICANCER-RESEARCH-34-4583-4588-2014
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos
Nature-Outlook-Article
GcMAF: our next-generation immunotherapy